Calcort: Advanced Glucocorticoid Therapy for Severe Inflammation
| Product dosage: 6 mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.55 | $46.44 (0%) | 🛒 Add to cart |
| 60 | $1.38 | $92.88 $82.56 (11%) | 🛒 Add to cart |
| 120 | $1.28 | $185.76 $153.94 (17%) | 🛒 Add to cart |
| 270 | $1.11 | $417.96 $298.42 (29%) | 🛒 Add to cart |
| 360 | $1.03
Best per pill | $557.28 $369.80 (34%) | 🛒 Add to cart |
Synonyms | |||
Calcort (deflazacort) is a synthetic glucocorticoid engineered to deliver potent anti-inflammatory and immunosuppressive effects with a potentially improved tolerability profile compared to some traditional corticosteroids. It is indicated for the treatment of a range of severe inflammatory and autoimmune conditions where standard therapies are insufficient. Its unique metabolic profile is designed to provide clinicians with a powerful tool for managing complex disease states while being mindful of the long-term sequelae of steroid therapy. This agent represents a significant option in the therapeutic arsenal for specialists managing chronic, debilitating inflammatory diseases.
Features
- Active Pharmaceutical Ingredient: Deflazacort (a prodrug converted to its active metabolite, 21-desdeflazacort).
- Pharmacological Class: Glucocorticoid.
- Available Formulations: Typically supplied as 6 mg and 30 mg tablets for precise dosage titration.
- Mechanism of Action: Exerts its effects by binding to cytoplasmic glucocorticoid receptors, modulating the transcription of genes responsible for the synthesis of pro-inflammatory mediators.
- Key Differentiator: May be associated with a lower propensity for certain metabolic side effects, such as fluid retention and hypertension, in some patient populations when compared to equipotent doses of prednisone.
Benefits
- Provides rapid and potent control of debilitating inflammatory responses, helping to restore patient function and quality of life.
- Offers a therapeutic option that may allow for effective disease management with a potentially reduced impact on weight gain and fluid balance in some individuals.
- Supports the management of acute exacerbations of chronic conditions, potentially reducing the frequency and duration of hospitalizations.
- Enables tailored dosing regimens to achieve optimal efficacy while working to minimize the cumulative risk of long-term adverse effects.
- Serves as a critical component in immunosuppressive regimens for autoimmune disorders, helping to prevent disease progression and organ damage.
Common use
Calcort is prescribed for the treatment of conditions where its potent anti-inflammatory and immunosuppressive properties are required. Its common uses include, but are not limited to, the management of inflammatory disorders of the musculoskeletal system such as rheumatoid arthritis and polymyalgia rheumatica. It is also utilized in severe cases of allergic states, dermatological diseases (e.g., pemphigus, severe psoriasis), respiratory conditions like sarcoidosis, and for the suppression of immune responses in organ transplantation. Its use is typically reserved for situations where the severity of the condition warrants systemic corticosteroid therapy and the benefit outweighs the potential risk.
Dosage and direction
Dosage must be individualized based on the specific disease being treated, its severity, and the patient’s response. The initial dosage may vary widely, often ranging from 6 mg to 90 mg daily, given as a single dose or in divided doses. The dosage should be titrated to the lowest possible level that provides adequate control of the clinical signs and symptoms. Due to the suppression of the hypothalamic-pituitary-adrenal (HPA) axis, withdrawal from treatment must be gradual. Abrupt discontinuation after prolonged therapy can lead to acute adrenal insufficiency. Therapy is typically initiated by a physician experienced in immunosuppressive and anti-inflammatory chemotherapy. Tablets should be taken with food to minimize potential gastrointestinal upset.
Precautions
Patients requiring Calcort therapy require close and continuous supervision. Precautions include monitoring for signs of infection, as corticosteroids can mask symptoms and increase susceptibility. Blood pressure, body weight, and serum electrolyte levels should be monitored regularly, especially with long-term use. Patients should be observed for signs of hyperglycemia, requiring possible adjustments in antidiabetic therapy. Ophthalmic examinations are recommended for patients on prolonged therapy to check for cataracts, glaucoma, and opportunistic eye infections. Use with extreme caution in patients with a history of peptic ulcer disease, diverticulitis, fresh intestinal anastomoses, and ulcerative colitis due to the risk of perforation. Behavioral and mood disturbances, including severe depression or euphoria, can occur and should be monitored.
Contraindications
Calcort is contraindicated in patients with known hypersensitivity to deflazacort or any of the excipients in the formulation. Systemic fungal infections are an absolute contraindication. Live or live-attenuated vaccines should not be administered to individuals who are immunosuppressed due to corticosteroid therapy. Relative contraindications, requiring a critical risk-benefit assessment, include untreated active infections (except in certain meningitis cases), latent tuberculosis, active peptic ulcer disease, uncontrolled hypertension, congestive heart failure, and recent myocardial infarction.
Possible side effect
A wide range of side effects is possible, correlating with dosage, duration of therapy, and individual patient susceptibility. Common side effects include fluid and electrolyte disturbances (sodium retention, fluid retention, hypokalemia, hypertension), musculoskeletal effects (muscle weakness, steroid myopathy, osteoporosis, vertebral compression fractures), gastrointestinal effects (peptic ulcer with possible perforation, pancreatitis, abdominal distention), dermatological effects (impaired wound healing, thin fragile skin, petechiae), neurological effects (convulsions, vertigo, headache), and metabolic effects (truncal obesity, hyperglycemia). Endocrine effects include development of cushingoid state and HPA axis suppression. Psychiatric effects such as euphoria, insomnia, mood swings, and depression may occur. Long-term use is associated with posterior subcapsular cataracts and glaucoma.
Drug interaction
The action of Calcort may be altered by concomitant administration of other drugs. CYP3A4 inducers (e.g., phenobarbital, phenytoin, rifampin) may enhance the metabolism of deflazacort, decreasing its efficacy and necessitating dosage adjustments. Conversely, CYP3A4 inhibitors (e.g., ketoconazole, macrolide antibiotics) may decrease its metabolism, increasing the risk of toxic effects. Concomitant use with diuretics may exacerbate electrolyte depletion, particularly hypokalemia. Its effects may be antagonized by cholestyramine. Corticosteroids may diminish the effect of antidiabetic agents, antihypertensives, and anticoagulants. The risk of gastrointestinal bleeding is increased with concurrent use of NSAIDs. Live vaccines should be avoided.
Missed dose
If a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped. The regular dosing schedule should be resumed, and a double dose should never be taken to make up for the missed one. Patients should be advised to contact their physician for specific guidance, particularly if they are on a tapering regimen, as this can disrupt the schedule for HPA axis recovery.
Overdose
Acute overdosage is not expected to cause acute life-threatening problems. However, chronic overdosage leads to the development of predictable, dose-dependent corticosteroid toxicities (Cushing’s syndrome). There is no specific antidote. Management consists of immediate gastric lavage or emesis if ingestion was recent, followed by supportive and symptomatic therapy. Treatment of hypertension, hypokalemia, and hyperglycemia may be necessary. In cases of chronic overdose, the dosage must be reduced gradually to avoid adrenal insufficiency.
Storage
Calcort tablets should be stored at room temperature (15°-30°C or 59°-86°F), in a tightly closed container, and protected from light, moisture, and excessive heat. The medication must be kept out of reach of children and pets. Tablets should not be used after the expiration date printed on the packaging. Do not flush medications down the toilet or pour them into a drain unless instructed to do so.
Disclaimer
This information is intended for educational and informational purposes only and does not constitute medical advice. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any new treatment. Never disregard professional medical advice or delay in seeking it because of something you have read in this document. The content has been compiled from various sources believed to be accurate and reliable; however, its completeness and accuracy cannot be guaranteed.
Reviews
“After struggling with severe polymyalgia rheumatica and the significant weight gain and edema associated with high-dose prednisone, my rheumatologist switched me to Calcort. The transition was managed carefully, and while it remains a powerful steroid, the difference in terms of fluid retention has been noticeable. It has provided the disease control I need with a slightly more manageable side effect profile.” – M.B., Age 68
“As an immunologist, having Calcort as an option is valuable, particularly for patients who are sensitive to the mineralocorticoid effects of other corticosteroids. It allows for effective immunosuppression while mitigating some of the cardiovascular and metabolic pressures we try to avoid in long-term management. It is a welcome tool in our protocol for certain autoimmune conditions.” – Dr. A. Sharma, MD